Stomach Cancer: Awareness, Early Detection and Where the Real Hope Is

June is Stomach cancer Awareness Month, and the urgency around Stomach cancer deserves far more attention than it currently receives. The disease is often silent in its early stages, which is exactly why awareness, early detection and honest messaging matter.

stomach cancer - gastric Adenocarcinoma in the great majority of cases - is among the most common cancers worldwide and among the more deadly ones. Yet it is also one of the few where a genuinely effective prevention lever exists, and where symptoms, once they appear, are easy to dismiss as indigestion, gastritis or reflux.

What Stomach cancer actually is

The Stomach is the hollow organ between the Oesophagus and the small intestine that mixes and empties food into the Duodenum. Cancer of the Stomach arises from the glandular cells lining the gastric wall. The two main subtypes are intestinal-type Adenocarcinoma, which behaves more like Colon cancer, and diffuse-type Adenocarcinoma, which tends to grow more aggressively and spread earlier.

Gastrointestinal stromal tumours are a separate family of cancers arising from specialised cells of the gastrointestinal wall and are usually managed differently. When this article refers to Stomach cancer, it means Adenocarcinoma.

Why it is found late

The reasons overlap with those seen in other deeply placed gastrointestinal cancers, but Stomach cancer has one distinctive pattern: the earliest signs are subtle and nonspecific.

Because the Stomach can accommodate distension, early tumours may cause little by way of symptoms. When symptoms do appear, they are frequently attributed to common, benign conditions - acid reflux, gastritis, functional dyspepsia, medication side effects. That diagnostic noise is the core reason survival remains tied so closely to stage at diagnosis.

Stage matters. Five-year survival for localised Stomach cancer is around 70 to 80 per cent, but falls sharply once there is nodal or distant spread. Awareness of the disease, and of the red flags, is therefore not merely symbolic.

The risk factors that are real

Helicobacter pylori

H. pylori is the single most important established risk factor. Chronic infection leads to atrophic gastritis, then intestinal metaplasia, then dysplasia, then Adenocarcinoma. Eradication of the bacterium reduces risk, particularly for the diffuse type, and is considered one of the most cost-effective cancer-prevention interventions available.

Smoking and diet

Smoking roughly doubles the risk of Gastric cancer. Diet plays a role too - high salt intake, smoked and pickled foods, and low fruit and vegetable intake are associated with higher risk. Alcohol is less clearly implicated than for some other gastrointestinal cancers, but it is not protective.

Family history and inherited syndromes

Familial clustering is common, and inherited syndromes such as hereditary diffuse Gastric cancer (CDH1) and Lynch syndrome increase risk. For carriers of CDH1, prophylactic Gastrectomy may be recommended, which is a major decision best made with a specialist genetics team.

Symptoms that matter

• Early satiety: feeling full quickly after starting a meal.
• Unexplained weight loss: losing weight without trying.
• Epigastric or abdominal pain: persistent discomfort in the upper abdomen.
• Nausea and vomiting: new or persistent.
• Gastrointestinal bleeding: with resulting anaemia.
• Dysphagia or palpable mass: later signs when the Tumour grows.

screening and surveillance

No broad population Screening programme for the disease is established in the way that exists for some other cancers, because the disease is relatively uncommon in the general population. The prevention lever is H. pylori testing and eradication, where infection is found.

For people at genuinely high risk - defined family history, inherited syndromes - specialist surveillance or prophylactic surgery is discussed. This is where family-history assessment matters most.

Treatment

Treatment is stage-dependent and delivered by a multidisciplinary team. Surgery remains the only curative option for localised disease, with total Gastrectomy plus lymphadenectomy for early tumours and subtotal Gastrectomy where appropriate.

• Surgery: Gastrectomy with lymphadenectomy for localised disease.
• chemotherapy: FLOT regimen (docetaxel, oxaliplatin, fluorouracil/leucovorin) perioperatively and/or adjectively.
• targeted therapy: trastuzumab for HER2-positive disease.
• Supportive care: early and integrated Palliative care.

What actually helps - the actions

1. Eradicate H. pylori where present.
2. Stop smoking.
3. Diet: reduce salt, avoid smoked and pickled foods, increase fruit and vegetables.
4. Know family history and discuss genetics if indicated.
5. Act on persistent symptoms - early satiety, weight loss, nausea, pain - rather than attributing them to benign causes.
6. If diagnosed, ask about FLOT, HER2-directed therapy and clinical trials.